Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.
Ursula A. Matulonis(Dana-Farber Cancer Institute), Daniela Matei(Northwestern University), Diane Provencher(Centre Hospitalier de l’Université de Montréal), Merry Jennifer Markham(University of Florida), Hal W. Hirte(Juravinski Cancer Centre), Yong Hao(Plex Pharmaceuticals (United States)), Harold Keer(Plex Pharmaceuticals (United States)), John C. Elkas, Gini F. Fleming(University of Chicago Medical Center), Sharad Ghamande(Augusta University Health), John Nemunaitis(Gradalis (United States)), Angeles Alvarez Secord(Duke University), Susana Banerjee(Royal Marsden NHS Foundation Trust), Sarah P. Blagden(Churchill Hospital), Amit M. Oza(Ontario Institute for Cancer Research), Lynda D. Roman(University of Southern California), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Bristi Basu(University of Cambridge), Sue Naim(Plex Pharmaceuticals (United States)), Mohammad Azab(Plex Pharmaceuticals (United States))
Cited by 8
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k